Review of Newer Antifungal and Immunomodulatory Strategies for Invasive Aspergillosis
Open Access
- 1 October 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 37 (s3) , S157-S187
Abstract
The incidence of invasive aspergillosis is markedly increasing, and mortality remains dismal. Previously there were only 2 antifungals with activityKeywords
This publication has 269 references indexed in Scilit:
- RECOMBINANT HUMAN MACROPHAGE COLONY-STIMULATING FACTOR AUGMENTS PULMONARY HOST DEFENCES AGAINST ASPERGILLUS FUMIGATUSCytokine, 2001
- Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patientsSupportive Care in Cancer, 2000
- In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens.European Journal of Clinical Microbiology & Infectious Diseases, 2000
- Analysis of Compassionate Use Itraconazole Therapy for Invasive Aspergillosis by the NIAID Mycoses Study Group CriteriaArchives of internal medicine (1960), 1997
- Pradimicins: A novel class of broad-spectrum antifungal compoundsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosisThe American Journal of Medicine, 1994
- The potential role of granulocyte-macrophage colony stimulating factor in therapy of fungal infections: A commentaryEuropean Journal of Clinical Microbiology & Infectious Diseases, 1994
- Inactivity of terbinafine in a rat model of pulmonary aspergillosisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- In vitro activity of the new semi-synthetic polypeptide cilofungin (LY121019) againstAspergillus andCandida speciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- Development of aspergillus sinusitis in a patient receiving amphotericin BThe American Journal of Medicine, 1984